| NCT ID | NCT07548372 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Montefiore Medical Center |
| Condition | Diabetes Mellitus |
| Study Type | INTERVENTIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2026-05-01 |
| Primary Completion | 2028-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20,000 participants in total. It began in 2026-05-01 with a primary completion date of 2028-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Continuous glucose monitoring (CGM) is a technology that helps individuals with diabetes track their sugar levels in real-time, leading to more in-range blood sugars, fewer episodes of dangerously low blood sugar, and improved quality of life. Despite these benefits, CGM is not widely used in primary care settings, where most people receive their diabetes care. The investigators aim to make CGM more accessible and equitably prescribed in primary care practices. The study team will support primary care to increase CGM use with a program called SPARK-CGM (Supporting Primary Care Adoption, Resources, and Knowledge for CGM) across a large network of primary care clinics at Montefiore Medical Center. This program will provide primary care providers (PCPs) with education, tools, and support to incorporate CGM into their routine care for people with diabetes. Investigators plan to test SPARK-CGM to evaluate whether it increases CGM prescriptions who are eligible to receive this technology.
Eligibility Criteria
Inclusion Criteria: Clinic level: * All adult Montefiore primary care sites * Clinician and clinic staff will be eligible if they provide direct patient care or are involved in CGM prescribing, authorization, onboarding, or education at participating primary care clinics. Eligible clinicians include physicians, nurse practitioners, physician assistants, and clinicians in training. Eligible clinic staff may include nurses, medical assistants, and other relevant administrative staff Patient level: * Age 18 years or older * Receive primary care at participating sites * Diagnosis of any diabetes mellitus * Treated with insulin therapy Exclusion Criteria: Clinic level: \- Sites participating in pilot phase of CGM initiative Patient level: \- Existing CGM prescription within 24 months before the study start
Contact & Investigator
Jovan Milosavljevic, MD
PRINCIPAL INVESTIGATOR
Montefiore Medical Center
Frequently Asked Questions
Who can join the NCT07548372 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diabetes Mellitus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07548372 currently recruiting?
Yes, NCT07548372 is actively recruiting participants. Contact the research team at rosina.antwi@einsteinmed.edu for enrollment information.
Where is the NCT07548372 trial being conducted?
This trial is being conducted at The Bronx, United States.
Who is sponsoring the NCT07548372 clinical trial?
NCT07548372 is sponsored by Montefiore Medical Center. The principal investigator is Jovan Milosavljevic, MD at Montefiore Medical Center. The trial plans to enroll 20,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.